Navigation Links
Neuralstem Updates ALS Stem Cell Trial Progress
Date:5/8/2012

ed an IND (Investigational New Drug) application to the FDA for a Phase I safety trial in chronic spinal cord injury.

Neuralstem also has the ability to generate stable human neural stem cell lines suitable for the systematic screening of large chemical libraries. Through this proprietary screening technology, Neuralstem has discovered and patented compounds that may stimulate the brain's capacity to generate new neurons, possibly reversing the pathologies of some central nervous system conditions.  The company has received approval from the FDA to conduct a Phase Ib safety trial evaluating NSI-189, its first small molecule compound, for the treatment of major depressive disorder (MDD).  Additional indications could include schizophrenia, Alzheimer's disease and bipolar disorder.

For more information, please visit www.neuralstem.com or connect with us on Twitter and Facebook.

Cautionary Statement Regarding Forward Looking Information

This news release may contain forward-looking statements made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements in this press release regarding potential applications of Neuralstem's technologies constitute forward-looking statements that involve risks and uncertainties, including, without limitation, risks inherent in the development and commercialization of potential products, uncertainty of clinical trial results or regulatory approvals or clearances, need for future capital, dependence upon collaborators and maintenance of our intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in Neuralstem's periodic reports, including the annu
'/>"/>

SOURCE Neuralstem, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. Neuralstem Announces Issuance of Core Technology Patent in Europe
2. Neuralstem Licenses Cleveland Clinic Spinal Cord Injection Technology
3. Neuralstems ALS Trial on Clinical Hold
4. Neuralstems Human Stem Cells Integrate into Nervous System of Rats with Animal Model of ALS
5. Neuralstem Receives FDA Approval to Commence Drug Trial for Major Depression
6. Neuralstem Receives FDA Orphan Designation for Spinal Cord Stem Cells for Treatment of ALS
7. Neuralstem Updates ALS Clinical Trial Progress
8. Dr. Eva Feldman, Principal Investigator, Presents Interim Safety Results for Neuralstem ALS Trial
9. Neuralstem Updates NSI-189 Major Depression Trial
10. Neuralstem Announces Notice of Allowance for Two Additional Neurogenic Compound Patents
11. Dr. Eva Feldman, Principal Investigator, Presents Interim Data on Neuralstem ALS Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... , May 21, 2013  IsoRay, Inc. (AMEX: ... that it has entered into an exclusive international distribution ... complete product line in Greece . ... seed brachytherapy and medical radioisotope applications for brain cancer, ... gynecologic ("gyn") cancer. IASIS Medical is ...
(Date:5/21/2013)... 2013 Hurel Corporation ("Hurel"), a world-leading provider ... platforms, today announced the appointment of James ... Board of Directors. Dr. MacDonald is the former Executive ... Institute ("SPRI"), which was the pharmaceutical development arm of ... Co. in 2009. Over a career that ...
(Date:5/21/2013)... BioElectronics Corp. (PINKSHEETS: BIEL), the maker ... that CEO, Andrew J. Whelan ... Advisory Committee, Orthopedic and Rehabilitation Panel compelling arguments ... counter sales. "It,s been 37 years ... schema," Whelan said.  "While the old classification of ...
Breaking Medicine Technology:IsoRay Announces A New International Distributor For Greece 2IsoRay Announces A New International Distributor For Greece 3Hurel Corporation Appoints Leading Pharmaceutical Executive and Toxicologist Dr. James S. MacDonald to Board of Directors 2BioElectronics Presents FDA Reclassification Panel 2BioElectronics Presents FDA Reclassification Panel 3
... NEW HAVEN, Conn., Aug. 5 Rib-X ... company focused on the,discovery and development of ... announced today that company,representatives are giving three ... Research Conference on Medicinal Chemistry, August 3-8, ...
... Aug. 5 Nexgen Spine, a leading,developer of ... disc disease, announced today that it has received ... Disc in the European,Union., "We are delighted ... mark approval," said Alastair Clemow, Ph.D., President and ...
Cached Medicine Technology:Rib-X Pharmaceuticals, Inc. Announces Recent and Upcoming Presentations at Scientific Conferences 2Rib-X Pharmaceuticals, Inc. Announces Recent and Upcoming Presentations at Scientific Conferences 3Nexgen Spine Receives CE Mark Approval for the Physio-L(R) Artificial Disc 2
(Date:5/21/2013)... glioblastoma brain tumor cells that uses a modified poliovirus ... establish the proper dose level, researchers at Duke Cancer ... tested in an ongoing phase 1 study, capitalizes on ... receptors that work like magnets drawing the poliovirus, which ... investigational therapy, known as PVSRIPO, uses an engineered form ...
(Date:5/21/2013)... 2013 STAR (Sensory Therapies And ... with sensory challenges and the Sensory Processing Disorder ... and advocacy of Sensory Processing Disorder present Stumbling Blocks ... Improve Quality of Life, a two-hour lecture presented by ... , Learn a method that can aid in ...
(Date:5/21/2013)... As the summer season kicks off, ... camp or beginning practice for summer or fall sports. ... or sporting activities can begin. , To help parents during ... youth sports or camp physicals at just $29. ... review a child’s medical history, perform a physical exam and ...
(Date:5/21/2013)... Diehard soccer fans will definitely want to ... the game between Manchester City and Chelsea FC ... These two teams are highly decorated in the English Premiere ... to the Busch Stadium, home of the St. Louis Cardinals, ... time that a professional sporting event and non-baseball game will ...
(Date:5/21/2013)... 21 (HealthDay News) -- Urban elementary school children ... sleep problems and suffer academically, new research indicates. ... seven to nine, we found that compromised lung ... impaired academic performance," said study author Daphne ... behavior at Brown University,s Alpert Medical School in ...
Breaking Medicine News(10 mins):Health News:Poliovirus vaccine trial shows early promise for recurrent glioblastoma 2Health News:STAR Center and SPD Foundation Present a Lecture on Teens and Adults with Sensory Processing Disorder 2Health News:STAR Center and SPD Foundation Present a Lecture on Teens and Adults with Sensory Processing Disorder 3Health News:MedSpring Offers Affordable Youth Physicals for $29 2Health News:Manchester City vs. Chelsea FC Tickets: Cheap Concert Tickets has Slashed Prices on Manchester City vs. Chelsea FC Tickets at Busch Stadium in St. Louis, MO 2Health News:Sleepless Nights May Hurt School Performance of Kids With Asthma 2
... Christian Davis Furman, M.D., M.S.P.H., vice chair for ... Medicine at the University of Louisville, has been selected ... Innovation Advisors Program. She is the only Kentuckian among ... of Columbia selected to participate. The ...
... New York (CCNY) whose research unites the divergent fields ... honored this month for his pioneering work in biomedical ... photonics. SPIE will present Dr. Robert Alfano, CUNY ... the first annual Britton Chance Biomedical Optics Award January ...
... FRIDAY, Jan. 6 (HealthDay News) -- If you,re 50 or ... screened for colorectal cancer, the American Society for Gastrointestinal Endoscopy ... cancers because most cases arise from precancerous growths in the ... exam and removed before they turn into cancer. Recent ...
... Fla. (Jan. 6, 2012) A malignancy-risk gene signature ... predictive and prognostic value for patients with early stage ... researchers at Moffitt Cancer Center in Tampa, Fla., who ... the Journal of the National Cancer Institute . ...
... Linagliptin (trade name: Trajenta) has been approved since August ... adults with type 2 diabetes mellitus whose elevated blood ... It is an option for patients who do not ... the drug metformin. Moreover, linagliptin can be added if ...
... Reinberg HealthDay Reporter , THURSDAY, Jan. 5 ... U.S. advisory panel,s recommendation to lower the threshold for ... once common in gasoline and house paint, can permanently ... Committee on Childhood Lead Poisoning Prevention voted to recommend ...
Cached Medicine News:Health News:UofL geriatrician selected for new federal Innovation Advisors Program 2Health News:CCNY's Robert Alfano wins first biomedical optics award 2Health News:CCNY's Robert Alfano wins first biomedical optics award 3Health News:Resolve to Take Colon Cancer Test, Experts Say 2Health News:Researchers find malignancy-risk gene signature for early-stage non-small cell lung cancer 2Health News:Added benefit of linagliptin is not proven 2Health News:Experts Endorse Lower Lead-Poisoning Threshold 2Health News:Experts Endorse Lower Lead-Poisoning Threshold 3
... The Vitros 950 provides power ... needs of high volume testing ... up to 900 results per ... store and perform the full ...
... Monitoring Market in 1981 with the introduction ... this system uses technology known as FPIA ... concentration in a patient. Therapeutic Drugs, used ... exhibit a narrow therapeutic range requiring close ...
AxSYM Plus provides cutting-edge ergonomics and smart new features that mean increased ease-of-use and enhanced reliability. Also, advanced software means less operator intervention and high-integrit...
Architect i2000SR provides high productivity. Seamless integration optimize performance....
Medicine Products: